KR20210082974A - Composition for preventing or treating metabolic disease comprising Nymphoides peltata extract - Google Patents

Abstract

The present invention relates to a composition for preventing or treating metabolic diseases containing a Nymphoides peltata extract. The Nymphoides peltata extract according to an aspect reduces blood sugar, body weight, and body fat in a high-fat diet mouse, and thus has effects of inhibiting liver damage, fatty liver production, lipid metabolism abnormality, and renal function impairment, thereby being able to be usefully used for preventing, treating or alleviating metabolic diseases.

Description

A composition for preventing or treating metabolic disease comprising an extract of Haengchae {Composition for preventing or treating metabolic disease comprising Nymphoides peltata extract}

It relates to a composition for preventing or treating metabolic diseases comprising the extract of Haengchae.

Metabolic disease is a disease in which risk factors for death such as obesity, diabetes, insulin resistance, fatty liver, hyperlipidemia, arteriosclerosis, or their complications exist together, and is also called 'metabolic syndrome'. The incidence of metabolic diseases is also rapidly increasing in Korea, and it is known that the incidence rate has significantly increased at or above the level of the United States and Western European countries.

Obesity refers to a condition in which energy intake and consumption are not balanced due to lifestyle or genetic causes, excess energy is accumulated as fat, and body fat is abnormally increased, and metabolic abnormalities are induced. Obesity is becoming more common among modern people due to the improvement of living standards following economic development, and it acts as a major cause of increasing the risk of hypertension, hyperlipidemia, arteriosclerosis, heart disease, and diabetes. As an anti-obesity drug sold at home and abroad, there is 'Xenical', which uses orlistat as its main ingredient, which has been approved by the US FDA. There are side effects.

Diabetes mellitus is a disease in which insulin secretion is insufficient or a normal function is not achieved, and is characterized by high blood sugar in which the concentration of glucose in the blood increases, and causes various symptoms and signs due to high blood sugar and excretes glucose in the urine. In addition, it is a disease that causes vascular disorders and malfunctions such as nerves, kidneys, and retina over a long period of time, leading to loss of life.

Dyslipidemia refers to a state in which total cholesterol, triglyceride, and LDL cholesterol concentrations in the blood are high or HDL cholesterol concentrations are low. When lipid components such as LDL cholesterol or triglycerides in the blood increase, blood flow becomes difficult and lipid components attach to the arterial wall, causing a chronic inflammatory reaction. . In the long term, the resulting thrombus blocks the coronary arteries or cerebral blood vessels, causing myocardial infarction, stroke or cerebral infarction (E. Falk et al., Circulation 92, 657-671, 1995).

Fatty liver medically means a pathological condition in which fat exceeds 5% of the total liver weight, and liver disease containing it is known as the second most serious disease after cancer in the cause of death of adults in their 40s and 50s in developed countries. About half of patients with cirrhosis, such as fatty liver, die from liver disease within 10 years of diagnosis. The causes of fatty liver are excessive drinking, obesity, diabetes, hyperlipidemia, and the like, and fatty liver has a very high risk of exacerbation into hepatitis, cirrhosis and liver cancer.

Drugs to treat these metabolic diseases have been developed, but a satisfactory treatment method or drug has not yet been developed. Accordingly, there is a need to develop a new natural material capable of preventing or treating metabolic diseases as described above without side effects.

One aspect is to provide a pharmaceutical composition for preventing or treating metabolic diseases containing an extract of Haengchae ( Nymphoides peltata ) as an active ingredient.

Another aspect is to provide a health functional food composition for the prevention or improvement of metabolic diseases containing Haengchae extract as an active ingredient.

Another aspect is to provide a method for preventing or treating a metabolic disease of an individual comprising administering to the individual an effective amount of a composition containing the Haengchae extract as an active ingredient.

One aspect provides a pharmaceutical composition for preventing or treating metabolic diseases containing an extract of Haengchae ( Nymphoides peltata ) as an active ingredient.

The Haengchae extract may be an extract extracted with a solvent from the whole plant of the Haengchae, a part thereof, or a material derived therefrom. The part may be an above-ground part, an underground part, a root, a stem, a leaf, a fruit, a flower, or a petal of the haengchae.

The scientific name of Haengchae is Nymphoides peltata (JGGmelin) Kuntze, and it is an aquatic perennial plant belonging to the Menyanthaceae family. Haengchae is distributed in Korea, China, Mongolia, Japan, and Europe, and may be one growing in the south central region. The main stem is columnar, hairless, flexible, with a diameter of 3-4mm, and grows obliquely in the water for a long time and leaves can float on the water surface. Roots are rhizomes, which can extend long and laterally. The leaves are long petioles, and the leaves that float on water resemble water lily leaves and can be shiny. The leaves are egg-shaped or round, 5-10 cm in diameter, and the lower part is divided into two, but some are attached, and the back side may be brownish purple. Flowers bloom in July-September similar to cucumber flowers, are bright yellow, grow in the leaf axil, and the length of peduncle can be 3-12 cm. The calyx lobe is broad lanceolate, the tip is dull, the corolla is 3-4 cm in diameter, has hairs on the edge, the tip is digged, and there may be 5 stamens and petals. The fruit is a capsule, a flat oval shape, somewhat longer than the calyx, and the tip is narrowed and becomes a style about 3mm long.

The solvent may be water, an alcohol, for example, a C1-C6 alcohol, for example, a C1-C4 alcohol, or a mixed solvent thereof. The C1-C6 alcohol may be methanol, ethanol, propanol, isopropanol, 1,3-propanediol, butanol, pentanol, hexanol, or the like. The solvent may be, for example, a mixture of water and alcohol, that is, an aqueous alcohol solution. The alcohol concentration of the aqueous alcohol solution is 1 to 99.5 (v/v)%, for example, 10 to 99.5 (v/v)%, 1 to 70 (v/v)%, 1 to 40 (v/v)%, 5 to 25 (v/v)%, 7 to 20 (v/v)%, 5 to 25 (v/v)%, or 10 to 20 (v/v)%. The aqueous alcohol solution may be an aqueous ethanol solution.

The extraction is performed by adding the extraction solvent 3 to 20 (volume/weight) times, for example, 3 to 16 (volume/weight) times, 3 to 14 times, with respect to the outpost, a part thereof, or a material derived therefrom of the haengchae. Extraction using (volume/weight) times, 3 to 7 (volume/weight) times, 3 to 5 (volume/weight) times, 5 to 10 (volume/weight) times, or 4 to 10 (volume/weight) times may be doing For example, 3 to 20 L of the extraction solvent may be added with respect to 1 kg of the forage, a part thereof, or a material derived therefrom of the haengchae.

The extraction is performed by warmed liquid extraction, pressurized liquid extraction (PLE), microwave assisted extraction (MAE), subcritical extraction (SE), or a combination thereof. can be The subcritical extraction may be subcritical water extraction (SWE). Subcritical water extraction is also referred to as superheated water extraction or pressurized hot water extraction (PHWE). The warmed liquid extraction may be reflux extraction.

The extraction may be performed at 4 °C to 90 °C, for example, 4 °C to 85 °C, 4 °C to 80 °C, 4 °C to 70 °C, 4 °C to 50 °C, 4 °C to 40 °C, 4 °C to 30 °C, 10 °C to 90 °C, 10 °C to 85 °C, 10 °C to 80 °C, 10 °C to 70 °C, 15 °C to 90 °C, 15 °C to 85 °C, 15 °C to 80 °C, 15 °C to 70 °C, 20 °C to 90 °C, 20 °C to 85 °C, 20 °C to 80 °C, 20 °C to 70 °C, 4 °C to 50 °C, 10 °C to 50 °C, 4 °C to 40 °C, 4 °C to 30 °C, 10 °C to 40 °C , 10 ℃ to 35 ℃, or may be carried out at 10 ℃ to 30 ℃. The extraction time may vary depending on the selected temperature, for example, 1 hour to 2 months, for example, 1 hour to 1 month, 1 hour to 15 days, 1 hour to 10 days, 1 hour to 5 days, 1 hour to 3 days. , 1 hour to 2 days, 1 hour to 1 day, 1 hour to 12 hours, 1 hour to 8 hours, 1 hour to 6 hours, 5 hours to 1 month, 5 hours to 15 days, 5 hours to 10 days, 5 hours to 5 days, 5 hours to 3 days, 5 hours to 2 days, 5 hours to 1 day, 10 hours to 1 month, 10 hours to 15 days, 10 hours to 10 days, 10 hours to 5 days, 10 hours to 3 days, or 10 hours to 2 days. The extraction may include mixing the whole plant, a part thereof, or a material derived therefrom in the solvent and leaving it for a certain period of time. The standing may include moderate agitation. The extraction may be repeated one or more times, for example, 1 to 5 times.

The extraction may be performed by separating plant residues and extracts by known methods such as filtration. The extraction may also include removing the solvent from the obtained extract by a known method such as concentration under reduced pressure. The extraction may also include preparing a dry extract by drying the obtained extract, such as freeze-drying.

As used herein, the term "metabolic disease" is a generic term for diseases caused by metabolic disorders in vivo, and specifically may include obesity, diabetes, hyperglycemia, dyslipidemia or fatty liver, etc. , but not limited thereto.

As used herein, the term “obesity” may refer to a state in which body fat is excessively accumulated. Obesity is defined as obesity when the body fat is 25% or more of body weight and 30 to 35% or more in women. As a general measurement method, body mass index (BMI ^{) expressed as weight (kg)/height (m) 2 ;} Body Mass Index) is widely used. When Western BMI 30kg / m ² is exceeded obesity, 25 ~ 30kg / m ² If the In and defined as overweight, in the case of the Orientals, the than 2 degree when low 28kg / m ² is exceeded obesity, 23 ~ 28kg / m ² can be considered overweight. In addition, obesity can be defined based on the waist to hip ratio (WHR; Waist to Hip Ratio) or the amount of abdominal fat, and in the present application, all cases of obesity defined by other conventional criteria, including the above criteria, are included. do.

As used herein, the term "dyslipidemia" may refer to a state in which lipid components such as triglycerides, LDL cholesterol, phospholipids and free fatty acids in the blood are increased or HDL cholesterol is decreased. The dyslipidemia may be, for example, any one or more selected from the group consisting of hyperlipidemia, high LDL cholesterol, hypertriglyceridemia and low HDL cholesterol.

The pharmaceutical composition may be to improve renal dysfunction caused by metabolic diseases. In addition, the pharmaceutical composition may be to improve liver damage caused by metabolic diseases.

As used herein, the term "treatment or amelioration" refers to or includes alleviation, progression inhibition or prevention of a disease, disorder, condition or condition, or one or more symptoms thereof, and a "pharmaceutically effective amount" refers to a disease, disorder, It may mean any amount of the composition used in the practice of the invention provided herein sufficient to alleviate, inhibit the progression or prevent the condition or condition, or one or more symptoms thereof. The effective amount (or dosage) is 0.1 mg to 1,000 mg, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg , 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg. The level of the effective amount depends on the type and severity of the subject, age, sex, drug activity, drug sensitivity, administration time, administration route and excretion rate, duration of treatment, factors including concomitant drugs, and other factors well known in the medical field. can be determined according to The pharmaceutical composition according to the present application may be administered so that, for example, the Haengchae extract is administered at 10 to 1,000 mg/kg, specifically, 10 to 600 mg/kg per day, it may be administered once or divided into several times. have.

The Haengchae extract is 0.001 wt% to 90 wt%, for example, 0.01 wt% to 80 wt%, 0.01 wt% to 60 wt%, 0.01 wt% to 40 wt%, 0.01 wt% to 30 wt% based on the total weight of the composition wt%, 0.01 wt% to 20 wt%, 0.01 wt% to 10 wt%, 0.01 wt% to 5 wt%, 0.05 wt% to 60 wt%, 0.05 wt% to 40 wt%, 0.05 wt% to 30 wt% , 0.05% to 20% by weight, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1 It may be included in an amount of 20% by weight to 20% by weight, 0.1% to 10% by weight, or 0.1% to 5% by weight.

The pharmaceutical composition may further include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol, and the lubricant may be magnesium stearate, talc, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be carboxymethyl cellulose calcium, sodium starch glycolate, anhydrous calcium monohydrogen phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

The pharmaceutical composition may be formulated as an oral or parenteral dosage form. Oral dosage forms may be granules, powders, solutions, tablets, capsules, dry syrups, or a combination thereof. The parenteral dosage form may be an injection.

The pharmaceutical composition may be administered orally or parenterally according to a desired method. Parenteral administration may include intraperitoneal, intrarectal, subcutaneous, intravenous, intramuscular or intrathoracic injection.

Another aspect provides a health functional food composition for the prevention or improvement of metabolic diseases containing Haengchae extract as an active ingredient.

The Haengchae extract and metabolic diseases are as described above.

As used herein, the term "health functional food" refers to a food manufactured using raw materials or ingredients that are easily deficient in daily meals or have a useful function in the human body, and refers to food that helps maintain the health of the human body. However, it is not limited thereto, and may be used in the sense of including all health foods in a normal sense.

The health functional food composition may be used alone, or may be used in combination with other foods or food ingredients, and may be appropriately used according to a conventional method. For example, the health functional food may be used in the form of tablets, capsules, powders, granules, liquids and pills. The mixing amount of the active ingredient may be appropriately determined depending on the intended use, and in general, the composition may be added in an amount of 0.01 to 90 parts by weight based on the total weight of the food. The food includes meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcohol, beverages, and vitamin complexes, etc. It is not limited and may include all health functional foods in a conventional sense.

The health functional food composition may further include a food pharmaceutically acceptable carrier. In addition, the health functional food may additionally include various flavoring agents, sweeteners, or natural carbohydrates. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The sweetener may be a natural sweetener such as taumatin or stevia extract, or a synthetic sweetener such as saccharin or aspartame.

The health functional food composition may also contain nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonated beverages It may include a carbonation agent used for, or a combination thereof. The health functional food composition may also include natural fruit juice, fruit juice beverage, fruit for the production of vegetable beverage, or a combination thereof.

The health functional food composition may be to improve renal dysfunction caused by metabolic diseases. In addition, the health functional food composition may be to improve liver damage caused by metabolic diseases.

Another aspect is to provide a method for preventing or treating a metabolic disease of an individual comprising administering to the individual an effective amount of a composition containing the Haengchae extract as an active ingredient.

The composition may be the above-described pharmaceutical composition or health functional food composition, as described above for the metabolic disease.

As used herein, the term "individual" refers to all animals, including humans, that have or are likely to develop a metabolic disease. The animal may be a mammal, such as a cow, a horse, a sheep, a pig, a goat, a camel, an antelope, a dog, a cat, and the like, in need of treatment for symptoms similar to those of a human, but is not limited thereto.

Specifically, the method for preventing or treating the metabolic disease may include administering the composition in a pharmaceutically effective amount to an individual who has or is likely to develop a metabolic disease.

Haengchae extract according to one aspect reduces blood sugar, body weight, and body fat in a high-fat diet mouse, and has an effect of inhibiting liver damage, fatty liver production, lipid metabolism abnormality, and renal function damage, so it is useful for the prevention, treatment or improvement of metabolic diseases It can be useful.

1 is a graph showing the results of measuring fasting blood glucose after the end of the experiment in a high-fat diet mouse model.
2 is a photograph of hematoxylin & eosin (H&E) staining of liver tissue after the end of the experiment in a high-fat diet mouse model.
3 is a graph showing the results of measuring the serum AST concentration in a high-fat diet mouse model.
4 is a graph showing the results of measuring the serum ALT concentration in a high-fat diet mouse model.
5 is a graph showing the results of measuring the total cholesterol concentration in the blood in a high-fat diet mouse model.
6 is a graph showing the result of measuring the blood triglyceride concentration in a high-fat diet mouse model.
7 is a graph showing the results of measuring blood LDL cholesterol concentrations in a high-fat diet mouse model.
8 is a graph showing the results of measuring blood creatinine concentration in a high-fat diet mouse model.
9 is a graph showing the results of measuring the amount of weight gain after the end of the experiment in a high-fat diet mouse model.
10 is a photograph of liver tissue in a high-fat diet mouse model (A) and a graph (B) as a result of measuring the weight of the liver tissue.
11 is a graph (B) of the result of measuring the weight of the epididymal adipose tissue photograph (A) and the epididymal adipose tissue of the high-fat diet mouse model.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes of one or more embodiments, and the scope of the present invention is not limited to these examples.

Example 1. Preparation of Haengchae extract

Haengchae ( Nymphoides peltata ) was purchased from Hantaek Botanical Garden (Korea). 20 g each of the dried haengchae above-ground part and the whole plant were immersed in 200 mL of primary distilled water, respectively, and extracted under reflux at 80° C. for 3 hours. This was repeated three times, and the obtained extract was dried under reduced pressure and concentrated to obtain a concentrate. The obtained haengchae above-ground part extract was 5.9758 g, and the yield was 29.8%, and the obtained haengchae whole plant extract was 5.5245 g, and the yield was 27.6%.

Example 2. Metabolic disease improvement effect of Haengchae extract

Example 2-1. High-fat diet-eating mice and drug dosing schedule

6-week-old C57BL/6J mice of 20-25 g were purchased from Orient Bio (Korea). Mice were bred in plastic cages and allowed to freely ingest water and feed in an animal room under the conditions of 23±2° C., 50±10% relative humidity, and light/dark cycle (12 hours/12 hours). After acclimatizing the mice to the animal room environment for one week before the start of the experiment, the control group (Con) received a regular diet with 10% calories, and the high fat diet group (HFD) received a high-fat diet with 60% calories for 16 weeks. paid while The experimental group was fed a high-fat diet for 16 weeks, and at the same time, the extract of the above-ground part of Haengchae or of the whole herb was orally administered once a day at a concentration of 100 mg/kg each.

Example 2-2. blood sugar lowering effect

In order to confirm the blood sugar lowering effect of Haengchae extract, fasting blood sugar in mice on a high fat diet was measured.

Specifically, the mice in each group after the 16-week experiment was completed according to Example 2-1 were fasted for 16 hours, and then fasting blood glucose was measured. Blood glucose was measured by Accu-Chek (Roche, Germany) by collecting blood from the tail vein of mice.

As a result, as shown in FIG. 1 , it was confirmed that the group administered with the above-mentioned haengchae extract and the group administered with the haengchae whole herb extract exhibited about 21% or more lower fasting blood sugar levels compared to the high-fat diet group.

Example 2-3. Inhibitory effect on liver damage (1)

In order to confirm the liver damage inhibitory effect of Haengchae extract, the liver tissue status of mice on a high fat diet was confirmed.

Specifically, according to Example 2-1, the mice in each group after 16 weeks of experimentation were anesthetized with ether, and liver tissue was excised. After the excised tissue was prepared in sections, hematoxylin & eosin staining was performed, and photographs were taken under a microscope for observation.

As a result, as shown in FIG. 2 , it was confirmed that a large amount of fat globules were confirmed in the liver tissue of the high-fat diet group, whereas the liver tissues of the group administered with the extract of the above-mentioned haengchae and whole herb extract showed a clean state similar to that of the control group. .

Example 2-4. Inhibitory effect on liver damage (2)

To confirm the liver damage inhibitory effect of Haengchae extract, the concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) enzymes, which are indicators of liver damage, were measured in the blood of mice on a high-fat diet.

Specifically, according to Example 2-1, after collecting the blood of mice from each group after 16 weeks of experimentation, the serum was separated from the collected blood, and the AST and ALT enzyme concentrations in the separated serum were analyzed using an analysis kit ( Asan Pharmaceutical, Korea) was used.

As a result, as shown in FIGS. 3 and 4 , it was confirmed that the concentration of AST and ALT enzymes in the high-fat diet group increased compared to the control group and significantly decreased in the group administered with the extract of the aerobic haengchae extract and the group administered with the haengchae whole herb extract.

Example 2-5. Inhibitory effect on lipid metabolism

In order to confirm the inhibitory effect of Haengchae extract on lipid metabolism abnormality, total cholesterol, triglyceride and LDL cholesterol concentrations in the blood of mice on a high-fat diet were measured.

Specifically, after separating mouse serum from each group in the same manner as described in Example 2-4, total cholesterol, triglyceride and LDL cholesterol concentrations in the blood were measured using an analysis kit (Asan Pharmaceutical, Korea).

As a result, as shown in FIGS. 5 to 7 , it was confirmed that the blood total cholesterol, triglyceride and LDL cholesterol concentrations of the high-fat diet group increased compared to the control group were significantly reduced in the group administered with the extract of the Aerial plant Haengchae extract and the group administered with the Haengchae whole plant extract.

Example 2-6. Inhibitory effect on renal function impairment

In order to confirm the inhibitory effect of the haengchae extract on renal function impairment, the blood creatinine concentration, which is an index of renal function, was measured in mice on a high-fat diet.

Specifically, after anesthetizing mice in each group after 16 weeks of experimentation according to Example 2-1 with ether, whole blood was collected from the abdominal aorta. After plasma was separated from the collected blood, the creatinine concentration was measured using a creatinine reagent (Roche, USA) and a hitachi modular device (Japan) by the rate blank Jaffe Kinetic method.

As a result, as shown in FIG. 8 , it was confirmed that the blood creatinine concentration of the high-fat diet group, which was increased compared to the control group, was significantly reduced in the group administered with the extract of Aerial plant Haengchae and the group administered with the extract of Haengchae whole plant.

Example 2-7. weight loss effect

In order to confirm the weight loss effect of Haengchae extract, the weight change of mice on a high fat diet was measured.

Specifically, during the 16-week experiment according to Example 2-1, the weights of mice in each group were measured at a constant time every day, and the weight on the experiment start day was subtracted from the weight on the experiment end day to determine the amount of weight gain during the experiment. The calculation is shown in FIG. 9 .

As a result, as shown in FIG. 9 , the body weight of the high-fat diet group was significantly higher than that of the control group, whereas the group administered with the extract of Haengchae aerial part and the group administered with the haengchae whole herb extract showed a significant weight loss compared to the high-fat diet group, The administration group showed a weight loss effect of about 36% compared to the high-fat diet group.

Examples 2-8. Inhibitory effect on fatty liver production

In order to confirm the effect of inhibiting fatty liver production of the haengchae extract, the liver was removed by sacrificing mice from each group after 16 weeks of experiment according to Example 2-1, and then the weight of the liver was measured, and the tissue state of the extracted liver. was confirmed.

As a result, as shown in FIG. 10 , compared to the control group, the liver of the high-fat diet group exhibited a lighter color and increased size due to the deposition of fat, whereas the liver of the group administered with the extract of the above-mentioned haengchae extract and the liver of the group administered with the haengchae extract was similar to the control group. condition, and liver weight was also significantly reduced compared to the high-fat diet group.

Examples 2-9. body fat reduction effect

In order to confirm the body fat reduction effect of the haengchae extract, the mice of each group after 16 weeks of experimentation were sacrificed according to Example 2-1 to extract the epididymal adipose tissue, and then the weight thereof was measured.

As a result, as shown in FIG. 11 , it was confirmed that the weight of epididymal adipose tissue increased in the high-fat diet group compared to the control group was significantly reduced in the group administered with the extract of Haengchae aboveground part and the group administered with the extract of Haengchae whole plant.

Claims (14)

Haengchae ( Nymphoides peltata ) A pharmaceutical composition for preventing or treating metabolic diseases containing an extract as an active ingredient. The pharmaceutical composition according to claim 1, wherein the Haengchae extract is extracted using water, C1-C6 alcohol, or a mixed solvent thereof as a solvent. The pharmaceutical composition according to claim 1, wherein the metabolic disease is obesity, diabetes, hyperglycemia, dyslipidemia, or fatty liver. The pharmaceutical composition according to claim 3, wherein the dyslipidemia is at least one selected from the group consisting of hyperlipidemia, hyperLDL cholesterolemia, hypertriglyceridemia and low HDL cholesterolemia. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is to improve renal dysfunction caused by metabolic diseases. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition improves liver damage caused by metabolic diseases. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. Haengchae ( Nymphoides peltata ) A health functional food composition for the prevention or improvement of metabolic diseases containing an extract as an active ingredient. The health functional food composition according to claim 8, wherein the Haengchae extract is extracted using water, C1-C6 alcohol, or a mixed solvent thereof as a solvent. The health functional food composition according to claim 8, wherein the metabolic disease is obesity, diabetes, hyperglycemia, dyslipidemia or fatty liver. The health functional food composition according to claim 10, wherein the dyslipidemia is at least one selected from the group consisting of hyperlipidemia, high LDL cholesterol, hypertriglyceridemia, and low HDL cholesterol. The method according to claim 8, wherein the health functional food composition is a health functional food composition to improve renal dysfunction caused by metabolic diseases. The method according to claim 8, wherein the health functional food composition is a health functional food composition that further comprises a food pharmaceutically acceptable carrier. The method according to claim 8, wherein the health functional food composition is a health functional food composition to improve the liver damage caused by metabolic diseases.

Images